BDP9066
BDP9066 is a potent and selective myotonic dystrophy-related Cdc42-binding kinase MRCK inhibitor with an IC50 of 64 nM for MRCKβ in SCC12 cells, Ki values of 0.0136 nM and 0.0233 nM for MRCKα/β in house determinations, respectively. BDP9066 has therapeutic effect on skin cancer by reducing substrate phosphorylation.
Product Specifications
CAS Number
[2226507-04-4]
UNSPSC
12352005
Target
Cdc42-binding kinase
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/BDP9066.html
Purity
98.49
Solubility
DMSO : 10 mg/mL (ultrasonic)
Smiles
C12=C(N3CCC[C@@]4(CCCCN4)C3)C=CNC1=NC=C2C5=NC=NC=C5
Molecular Formula
C20H24N6
Molecular Weight
348.44
References & Citations
[1]Unbekandt M, et al. Discovery of Potent and Selective MRCK Inhibitors with Therapeutic Effect on Skin Cancer. Cancer Res. 2018 Apr 15;78 (8) :2096-2114.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
MRCKβ
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
